Bangalore, Karnataka -- (SBWIRE) -- 07/19/2016 -- An increase in any particular internal and external factor can lead to cancer. Currently, the demand for cancer therapy and research in complex molecular tumor diagnostics is high. Researchers are using automated solutions to isolate genetic materials from small tissue samples. The complex genetic analysis of samples using next-generation sequencing technologies helps researchers analyze the individual and relevant pattern of genetic changes in tumor tissues, helping in determining the most effective treatment options.

The development of sophisticated technologies such as microarray, next-generation sequencing, mass spectrometry, automated DNA sequencing, fluorescence in-situ hybridization, and comparative genomic hybridization has opened new avenues for cancer biomarkers. These technologies are capable of detecting abnormalities in the gene expression and the genetic structure of cancer cells. In addition, these technologies can analyze changes in the DNA, RNA, and chromosomes from tissue samples of a tumor.

Report forecast the global cancer diagnostics devices market to grow at a CAGR of 18.07% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global cancer diagnostics devices market for 2016-2020 To calculate the market size, we consider revenue generated from the sales of molecular and companion cancer diagnostic devices.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Global Cancer Diagnostics Devices Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Abbott Diagnostics
- Agilent Technologies
- BD
- bioMérieux
- Qiagen
- Roche Diagnostics

Other prominent vendors
- Affymetrix
- Ambry Genetics
- Annoroad
- Aviva Biosciences
- Biochain
- Bio-Rad
- Cancer Genetics
- Cepheid
- CompanionDx
- DiagnoCure
- Epic Sciences
- Epigenomics
- Genomic Health
- HalioDX
- Hologic
- Illumina
- Myriad Genetics
- Thermo Fisher Scientific
- Ventana Medical Systems
- Vysis

Market driver
- Demand for personalized medicines
- For a full, detailed list, view our report

Market challenge
- High cost of developing companion diagnostics
- For a full, detailed list, view our report

Market trend
- Demand for personalized medicines
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 67 pages "Global Cancer Diagnostics Device Market 2016-2020" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Cancer statistics, Market landscape, Reimbursement and coverage: An overview, Cancer diagnostic devices: Pricing scenario, Market segmentation by product, Market segmentation by cancer type, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Key vendors, Appendix.

For more information Visit at: http://www.drugpipeline.net/technavio/global-cancer-diagnostics-device-market-2016-2020

Related Report:

Global Extremity Products Market 2016-2020; visit - http://www.drugpipeline.net/technavio/global-extremity-products-market-2016-2020

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.